Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 3
1962 1
1963 2
1976 1
1977 2
1980 4
1981 1
1982 2
1983 3
1984 2
1985 3
1986 4
1988 2
1989 4
1990 1
1991 1
1992 1
1993 2
1994 1
1996 3
1997 1
1998 3
1999 1
2000 3
2001 2
2002 1
2003 1
2004 3
2005 3
2006 3
2007 2
2008 6
2009 3
2010 1
2011 2
2012 1
2013 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Emerging MEK inhibitors.
McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. McCubrey JA, et al. Among authors: bonati a. Expert Opin Emerg Drugs. 2010 Jun;15(2):203-23. doi: 10.1517/14728210903282760. Expert Opin Emerg Drugs. 2010. PMID: 20151845 Review.
Emerging Raf inhibitors.
McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. McCubrey JA, et al. Among authors: bonati a. Expert Opin Emerg Drugs. 2009 Dec;14(4):633-48. doi: 10.1517/14728210903232633. Expert Opin Emerg Drugs. 2009. PMID: 19715444 Review.
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.
Mazzera L, Abeltino M, Lombardi G, Cantoni AM, Jottini S, Corradi A, Ricca M, Rossetti E, Armando F, Peli A, Ferrari A, Martinelli G, Scupoli MT, Visco C, Bonifacio M, Ripamonti A, Gambacorti-Passerini C, Bonati A, Perris R, Lunghi P. Mazzera L, et al. Among authors: bonati a. Leukemia. 2023 Aug;37(8):1671-1685. doi: 10.1038/s41375-023-01940-x. Epub 2023 Jun 29. Leukemia. 2023. PMID: 37386079 Free PMC article.
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA. Chappell WH, et al. Among authors: bonati a. Oncotarget. 2011 Mar;2(3):135-64. doi: 10.18632/oncotarget.240. Oncotarget. 2011. PMID: 21411864 Free PMC article. Review.
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA. Steelman LS, et al. Among authors: bonati a. Leukemia. 2008 Apr;22(4):686-707. doi: 10.1038/leu.2008.26. Epub 2008 Mar 13. Leukemia. 2008. PMID: 18337767 Review.
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.
Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA. Steelman LS, et al. Among authors: bonati a. Aging (Albany NY). 2011 Mar;3(3):192-222. doi: 10.18632/aging.100296. Aging (Albany NY). 2011. PMID: 21422497 Free PMC article. Review.
Targeting the cancer initiating cell: the ultimate target for cancer therapy.
McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Basecke J, Nicoletti F, Libra M, Ligresti G, Stivala F, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Bonati A, Evangelisti C, Cocco L, Martelli AM. McCubrey JA, et al. Among authors: bonati a. Curr Pharm Des. 2012;18(13):1784-95. doi: 10.2174/138161212799859701. Curr Pharm Des. 2012. PMID: 22394167 Review.
82 results